Prof. Dr. Yanchuan Li | Nanjing Medical University | China
Dr. Yanchuan Li (李砚川), born in 1985 in Pingxiang, Jiangxi, is a distinguished cancer immunology researcher. He earned his Ph.D. in Biochemistry and Molecular Biology from Peking Union Medical College (Tsinghua University School of Medicine) in 2016 under the mentorship of Academician Linfang Wang and Prof. Shao-Cong Sun. Currently, he is a Professor and Ph.D. advisor at Nanjing Medical University, focusing on tumor and immune research. His expertise spans lymphocyte receptor signaling, CAR-NKT cell therapy, and molecular immunology. His groundbreaking research has been published in Cell Research, Blood, JEM, and Nature Communications. He also serves as a reviewer for top journals like Cellular & Molecular Immunology, Nucleic Acids Research, and Molecular Therapy. 🎓🔍
Professional Profile:
Google Scholar
Suitability for Best Researcher Award
Dr. Yanchuan Li is a highly suitable candidate for a Best Researcher Award due to his exceptional contributions to cancer immunology and molecular immunology. Dr. Li’s expertise in lymphocyte receptor signaling, CAR-NKT cell therapy, and tumor immunology has significantly advanced the understanding of immune regulation in cancer. His research impacts both fundamental immunological mechanisms and translational applications, making him a distinguished figure in the field.
Education & Experience 📚👨🔬
- 2012-2016 🎓 Ph.D. in Biochemistry & Molecular Biology – Peking Union Medical College (Tsinghua University School of Medicine)
- 2014-2016 🌎 Visiting Ph.D. Scholar – MD Anderson Cancer Center, USA (CSC Scholarship)
- 2016-2021 🧪 Postdoctoral Research Fellow – MD Anderson Cancer Center, USA
- 2021-2022 🏥 Research Scientist – MD Anderson Cancer Center, USA
- 2022-2023 🔬 Research Associate – Baylor College of Medicine, USA
- 2023-Present 🎓 Professor & Ph.D. Supervisor – Nanjing Medical University
Professional Development 🔬📈
Dr. Li’s research bridges fundamental tumor immunology and translational medicine, employing cell culture, gene manipulation, proteomics, and multi-omics approaches. His work utilizes CRISPR/Cas9 screening, single-cell analysis, and knockout mouse models to uncover key immune signaling mechanisms. His significant contributions to B cell function, CAR-NKT therapy, and immune regulation in major diseases are paving the way for innovative cancer treatments. He has played a key role in developing CAR-NKT cell therapies, including a clinical trial for relapsed neuroblastoma. His dedication to scientific excellence and interdisciplinary collaboration is shaping the future of cancer immunotherapy. 🏥🧬💡
Research Focus 🔍🦠
Dr. Li’s research covers tumor immunology and translational medicine, with key interests in:
1️⃣ B Cell Function & Autoimmunity – Exploring B cell activation in diseases like SLE & B cell leukemia. 🔬🦠
2️⃣ CAR-NKT Cell Therapy – Engineering NKT cells for safer and more effective cancer immunotherapy. 🎯💉
3️⃣ Molecular Mechanisms of Major Diseases – Utilizing multi-omics & disease models to investigate cancer progression, autoimmune disorders, and drug response. 🧪📊
4️⃣ Advanced Immuno-Analytical Techniques – Developing single-cell spatial transcriptomics, CRISPR-based screens, and novel proteomics to revolutionize cancer research. 🔍🔬
Awards & Honors 🏆🎖️
- 🏅 Outstanding Ph.D. Graduate – Peking Union Medical College, 2016
- 🏅 Outstanding Ph.D. Graduate – Beijing Municipality, 2016
- ⭐ Annual Excellence Award – Nanjing Medical University, 2023
- 💰 West Taihu Cell Therapy Foundation Grant – 500,000 CNY
Publication Top Notes:
📢 Proinflammatory TLR signalling is regulated by a TRAF2-dependent proteolysis mechanism in macrophages – Cited by 97 🔬
🧬Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results – Cited by 87 🏥
🦠 TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis – Cited by 78 🧫
🛡Cell intrinsic role of NF-κB-inducing kinase in regulating T cell-mediated immune and autoimmune responses – Cited by 67 🏋️
🧩 Preventing abnormal NF-κB activation and autoimmunity by Otub1-mediated p100 stabilization – Cited by 44 🏗
🦠 NIK signaling axis regulates dendritic cell function in intestinal immunity and homeostasis – Cited by 44 🦠
🔥 Peli1 facilitates NLRP3 inflammasome activation by mediating ASC ubiquitination – Cited by 43 🚀
🧠 Microglia promote autoimmune inflammation via the noncanonical NF-κB pathway – Cited by 42 🧠
🌿 Protective effect of melatonin on cigarette smoke‐induced restenosis in rat carotid arteries after balloon injury – Cited by 40 🌙
🦠 Intestinal epithelial TBK1 prevents differentiation of T-helper 17 cells and tumorigenesis in mice – Cited by 30 🏥